Dose escalated radiotherapy improves outcomes for men with prostate cancer. A plateau for
benefit from dose escalation using EBRT may not have been reached for some patients with …

Stereotactic body radiotherapy (SBRT) is a technologically sophisticated form of
radiotherapy that holds significant potential to effectively treat high-risk prostate cancer …

Purpose This is the first report of the 2SMART Phase II trial evaluating the safety of two-
fraction stereotactic ablative radiotherapy (SABR) with focal boost to magnetic resonance …

Purpose To compare biochemical outcome and toxicities of two prospective 5-fraction
stereotactic ablative radiotherapy (SABR) studies in prostate cancer. Materials and methods …

Purpose Ultrahypofractionation is appealing for prostate cancer (PCa) due to low α/β, and
increasing the dose per fraction could improve the therapeutic index. Here we report the …

Purpose There is no evidence-based data to guide dose constraints in two-fraction prostate
stereotactic ablative radiotherapy (SABR). Using individual patient-data from two …

Stereotactic body radiotherapy (SBRT) for prostate cancer (PCa) is gaining interest by the
recent publication of the first phase III trials on prostate SBRT and the promising results of …

Purpose Stereotactic body radiotherapy (SBRT) is an emerging treatment option for
localized prostate cancer. There is increasing interest to reduce the number of fractions for …

Prostate cancer is the most commonly diagnosed cancer among men around the world.
Radiotherapy is a standard of care treatment option for men with localized prostate cancer …

Purpose Dose-escalated stereotactic ablative radiotherapy (SABR) to the whole prostate
may be associated with better outcomes but has a risk of increased toxicity. An alternative …